The world market for cancer therapeutics and biotherapeutics
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

The world market for cancer therapeutics and biotherapeutics

  • 942 views
Uploaded on

One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself......

One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
942
On Slideshare
942
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
6
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition (Pre-Publication)Published: October2011No. of Pages: 245Price: $ 2995This Kalorama Information report - The World Market for Cancer Therapeutics andBiotherapeutics, 4th Edition - focuses on several segments for cancer treatment including:• Chemotherapy, including -subcategories Alkylating Agents, Antimetabolites, CytotoxicAgents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodarwith Market Share for each• Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists,Aromatase Inhibitors and SERMS-Brands such as Arimidex, Casodex, Zoladex, Femara andLupron with Market Share for each.• Immunotherapy and Biotherapy, including: -Monoclonal antibodies,interleukins/interferons, vaccines and other biotherapy-Brands such as Rituxan, Herceptin,Gleevec, Evastin and ErbituxOne of the most promising new approaches in modern cancer treatment is immunotherapyor biotherapy, the development of methods to augment and enhance the body’s naturaltendency to defend itself against malignant tumors without damaging healthy tissue. Thereport devotes particular attention to these new therapies.This report, Kaloramas fourth complete research effort into the oncology treatments marketin the past ten years, provides cancer treatment market size information for the varioustypes of cancers including the following:• Bladder• Breast• Cervical• Colorectal• Esophageal• Head/Neck• Kidney• Leukemia
  • 2. • Liver• Lung• Lymphoma• Melanoma• Multiple Myeloma• Neuroblastoma• Ovarian• Pancreatic• Prostate• StomachBrowse All: Pharmaceuticals Market Research ReportsThe report covers both currently marketed and late stage development cancer products.Revenues for each current market segment were generated using dollar and unit sales foreach product.The report includes statistical information for cancers by type worldwide, with specialemphasis on the U.S. market. Specifically, cancers where there are current productsavailable or are in development and/or have significant incidence/mortality rates areprofiled. The market segments provide an overview, description of products on the market,leading product sales, market estimates and forecasts, and competitive analysis of leadingproviders. The report also includes a list of products in development and current issues andtrends affecting the industry.The information for this report was gathered using both primary and secondary researchincluding comprehensive research of secondary sources such as company literature,databases, investment reports, and medical and business journals. Telephone interviewsand email correspondence were the primary method of gathering information. For thepurpose of this study Kalorama Information conducted interviews with key industry officials,consultants, health care providers, and government personnel. These sources were theprimary basis in gathering information specifically relating to revenue and market sharedata presented in this report. Specific interviews with pharmaceutical companyrepresentatives included marketing directors, division managers, and productrepresentatives.As part of its coverage, the report looks at the following trends• Insurance and Reimbursement Issues• Cancer Drug Costs
  • 3. • Personalized Medicine• Targeted Cancer Therapy• Pharmacogenomics• Alliances Acquisitions and Licensing Agreements• Patient-Reported Outcomes• Alcohol’s Affect on Cancer Incidence• Healthy Lifestyles Continue to Show Promise for Cancer Prevention• Obesity in the U.S.• Outlook for a Healthier U.S. Population• Cancer Trends• Marketing and Distribution Trends• Geographical Trends (US, Europe, Japan)• Elderly Clinical Trial Involvement• Late-Stage Drug Development TrendsAll market data pertains to the world market at the manufacturers’ level. The base year fordata was 2010. Historical data was provided for the years 2005 through 2009, with forecastdata provided for 2011 through 2015. Compound annual growth rates (CAGRs) are providedfor the 2005-2010, 2010-2015 and 2005-2015 periods for each industry segment covered.Competitive analysis is provided for the year 2010. The forecasted market analysis for2010-2015 was based on probability of approval and sales of products in late stagedevelopment, competitive trends, product marketing, and demographic trends.Table Of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and Trends Affecting Market Leading CompetitorsCHAPTER TWO: INTRODUCTION What is CancerBiochemistry of Cancer CellsCarcinogen MetabolismCauses of Cancer GrowthEnvironmental Factors, DNA, RNACellular OncogenesTumor Suppressor Genes History and Growth of the Cancer Treatment Market
  • 4. Industry StructureProduct Segments and TechnologyChemotherapy: At a GlanceHormone Therapy: At A GlanceBiotherapy: At A GlanceRadiation Therapy: At a Glance Demographics and StatisticsGlobal Cancer StatisticsDemographicsAging Population Life Expectancy and CancerLife ExpectancyBirth Rates Description of CancersBladder CancerBrain CancerGlioblastomaNeuroblastomaBreast CancerCervical CancerColorectal CancerEsophageal CancerHead and NeckKidneyLeukemiaLiverLung CancerLymphomaMelanomaMultiple MyelomaOvarian CancerPancreasProstate CancerStomach CancerCHAPTER THREE: CHEMOTHERAPYOverviewProduct Descriptions and ExamplesAlkylating AgentsAntimetabolitesCytotoxic AgentsPlant DerivativesMarket Size and GrowthMarkets by Product TypeMarkets by Geographical SegmentsU.S. MarketEuropean MarketJapan MarketROW MarketMarket Data by IndicationCompetitive AnalysisCHAPTER FOUR: HORMONE THERAPY
  • 5. Overview Product Descriptions and ExamplesCorticosteroidsHormone Agonists and AntagonistsAromatase InhibitorsSelective Estrogen Receptor Modulators (SERMs) Market Size and GrowthMarkets by Product TypeMarkets by Geographical SegmentsU.S. MarketEurope MarketJapan MarketROW MarketMarket Data by Indication Competitive AnalysisCHAPTER FIVE: BIOTHERAPEUTICS Overview Product Descriptions and ExamplesMonoclonal AntibodieInterleukins/InterferonsTyrisoine Kinase InhibitorsOther BiotherapeuticsRadioimmunotherapy Market Size and GrowthMarkets by Product TypeMarkets by Geographical Segments U.S. Market Europe Market Japan Market ROW MarketMarket Data by Indication Competitive AnalysisCHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECASTOverviewTotal Market Size and ForecastGeographical Market DistributionCompetitive LandscapeCHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKETIntroductionInsurance and Reimbursement IssuesCancer Drug CostsPersonalized MedicineTargeted Cancer TherapyPharmacogenomicsAlliances Acquisitions and Licensing AgreementsPatient-Reported OutcomesAlcohol’s Affect on Cancer IncidenceHealthy Lifestyles Continue to Show Promise for Cancer PreventionObesity in the U.S.U.S. Obesity Rates Differ Among Ethnic GroupsOutlook for a Healthier U.S. Population
  • 6. Cancer Trends Marketing and Distribution Trends Geographical TrendsUnited StatesEuropeJapan Elderly Clinical Trial Involvement Late-Stage Drug Development TrendsSignificant Developments Alpharadin Afatinib Axitinib Bosutinib Brentuximab Carfilzomib Crizotinib Erwinaze Exelbine Motesanib Omnitarg Regorafenib Ridaforolimus Zaltrap Recent NDA Activity New ApprovalsCHAPTER EIGHT: CORPORATE PROFILESIntroductionAstraZeneca plcBristol-Myers Squibb CompanyEli Lilly & CompanyJohnson & JohnsonMerck & Company, Inc.Novartis AGPfizer, Inc.RocheSanofiAPPENDIX: MAJOR COMPETITOR DIRECTORYLIST OF EXHIBITSEXECUTIVE SUMMARYTable 1-1World Cancer MarketMarket by Product Type, 2005-2015Figure 1-1World Cancer Market, Market by Product Type Revenues, 2005-2015Figure 1-2World Cancer Market, Market by Product Type and Percent Market Share, 2010INTRODUCTIONTable 2-1 Viruses Associated with Cancer in HumansFigure 2-1 Approved Cancer Therapies in the United States by Primary IndicationTable 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races,
  • 7. both sexes Figure 2-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer,2010 and 2020 Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates Figure 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates Table 2-4 World Population by Selected Geographical Region, 2010 - 2050 Figure 2-4 World Population by Selected Geographical Region, 2010-2050 Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050 Figure 2-5 Estimated World Population by Age, 2010 and 2050 Table 2-6 Average Life Expectancy in Years by Country 1980, 2004 and 2009 Figure 2-6 Average Life Expectancy in Years by Country 1980 and 2009 Table 2-7 United States Average Years of Life Lost Per Person Dying of Cancer, All Races,Both Sexes, 2006 Table 2-8 United States Estimated Person-Years of Life Lost Due to Cancer, All Races,Both Sexes, 2006 Table 2-7 Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010 Figure 2-9 Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010 Table 2-8 TYPES OF LEUKEMIA Table 2-9 TYPES OF PRIMARY LUNG CANCER Table 2-10 CLASSIFICATION OF NON-HODGKIN’S LYMPHOMAS Table 2-11 MALIGNANT CONDITIONS OF THE SKINCHEMOTHERAPY Table 3-1 Leading Products, 2010 Table 3-2 World Chemotherapy Market, 2005-2015 Figure 3-1 World Chemotherapy Market, 2005-2015 Table 3-3 World Chemotherapy Market, Sales by Drug Classification, 2010 Figure 3-2 World Chemotherapy Market Table 3-4 World Chemotherapy Market, Sales by Drug Classification, Estimated 2015 Figure 3-3 World Chemotherapy Market Figure 3-4 World Chemotherapy Market Figure 3-5 World Chemotherapy Market Table 3-5 World Chemotherapy Market Figure 3-6 World Chemotherapy Market Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market Revenues,2010 Figure 3-7 World Chemotherapy Market, Leading Suppliers Market Share, 2010CHATPER FOUR: HORMONE THERAPYTable 4-1 Leading Products, 2010Table 4-2 World Hormone Therapy Market, 2005-2015Figure 4-1 World Hormone Therapy Market, 2005-2015Table 4-3 World Hormone Therapy Market, Sales by Drug Classification, 2010Figure 4-2 World Hormone Therapy Market, Market by Drug Classification and PercentMarket Share, 2010Table 4-4 World Hormone Therapy Market, Sales by Drug Classification, Estimated 2015Figure 4-3 World Hormone Therapy Market, Market by Drug Classification and PercentMarket Share, 2015Figure 4-4 World Hormone Therapy MarketFigure 4-5 World Hormone Therapy MarketTable 4-5 World Hormone Therapy MarketFigure 4-6 World Hormone Therapy Market
  • 8. Table 4-6 World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues,2010 Figure 4-7 World Hormone Therapy Market, Leading Suppliers Market Share, 2010CHAPTER FIVE: BIOTHERAPEUTICS Table 5-1 Leading Products, 2010 Table 5-2 World Cancer Biotherapeutics Market, 2005-2015 Figure 5-1 World Cancer Biotherapeutics Market, 2005-2015 Table 5-3 World Biotherapeutics Market, Sales by Drug Classification, 2010 Figure 5-2 World Biotherapeutics Market Table 5-4 World Biotherapeutics Market, Sales by Drug Classification, Estimated 2015 Figure 5-3 World Biotherapeutics Market Figure 5-4 World Cancer Biotherapeutics Market Figure 5-5 World Cancer Biotherapeutics Market Table 5-5 World Cancer Biotherapeutics Market Figure 5-6 World Cancer Biotherapeutics Market Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues,2010 Figure 5-7 World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2010WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST Table 6-1 World Cancer Market Market by Product Type, 2005-2015 Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2005-2015 Figure 6-2 World Cancer Market, Market by Product Type and Percent Market Share, 2010 Figure 6-3 World Cancer Market, Market by Product Type and Percent Market Share, 2015 WorldCancer Market Table 6-2 World Cancer Market, Leading Suppliers’ Shares by Market Revenues, 2010 Figure 6-5 World Cancer Market, Leading Suppliers’ Market Share, 2010ISSUES AND TRENDS AFFECTING THE CANCER MARKET Table 7-1 Obesity Rates by U.S. State, 2009 Table 7-2 Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Table 7-2 (continued) Select Products in Development by Development Phase Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications,Distribution EstimatesTable 7-3 Recent NDA Activity: January 2011-July 2011Table 7-4 Select New Approvals NCE, Indications, Dosage, Formulations) January 2010-July 2011Table 7-4 (continued) Select New Approvals (NCE, Indications, Dosage, Formulations)January 2010-July 2011CORPORATE PROFILES
  • 9. Figure 8-1 Late stage Cancer Therapies in Development for Leading CompaniesAbout Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog